Jeffrey S. Albert

Pharmacologic Schizophrenia

Herausgegeben von Wood, Michael W.

• Gebundenes Buch

Produktbeschreibung

Covering a wide range of receptors and molecular targets, this book provides a comprehensive resource for neuro drug discovery and molecular targets for schizophrenia. Focusing on current research and applications, the text describes novel mechanisms of action that can overcome shortcomings in existing schizophrenia drugs.

---

This book provides a comprehensive resource for neuro drug discovery and molecular targets for schizophrenia, from current therapies to evolving targets. The coverage begins with a discussion of prevalence and etiology, and an introduction to current therapies (which treat only certain, "positive" symptoms), as well as the rise of interest in addressing untreated symptoms. Subsequent sections focus on each major mechanistic hypothesis, beginning with a chapter that serves as an introduction and overview. Within these models, chapters focus on each major pharmacological target and address both the neurobiological and chemical aspects of that target.

Produktdetails

• Verlag: Wiley & Sons
• 1. Auflage
• Seitenzahl: 486
• Erscheinungstermin: 10. Juli 2012
• Englisch
• Abmessung: 240mm x 161mm x 31mm
• Gewicht: 815g
• ISBN-13: 9780470322826
• ISBN-10: 0470322829
• Artikelnr.: 34743779

Autorenporträt

JEFFREY S. ALBERT, PhD, is a Project Leader and Head of Lead Generation Chemistry in AstraZeneca's neuroscience department. He has authored or coauthored more than forty publications, mostly focusing on novel therapeutic targets involved in depression, schizophrenia, and Alzheimer's disease and on the development and application of fragment-based lead generation methodologies. MICHAEL W. WOOD, PhD, is an External Collaborations Director in AstraZeneca's neuroscience unit where he is responsible for coordinating research to deliver novel therapeutics targeting schizophrenia as well as other neuroscience treatments. He has been focused on neuroscience drug discovery research for fifteen years.

Inhaltsangabe

Preface vii Contributors xi Introduction 1 Alan J. Cross 1 Dopaminergic
Hypothesis of Schizophrenia: A Historical Perspective 5 Aurelija Jucaite
and Svante Nyberg 2 Dopamine D2/D3 Partial Agonists as Antipsychotics 37
Philip G. Strange 3 D1/D5 Dopamine Agonists as Pharmacotherapy for
Schizophrenia 51 Kevin N. Boyd and Richard B. Mailman 4 Phosphodiesterase
Inhibitors as a Novel Therapeutic Approach for Schizophrenia 85 Judith A.
Siuciak and William J. Pitts 5 Glutamatergic Synaptic Dysregulation in
Schizophrenia 115 Joseph T. Coyle, Alo Basu, and Michael Benneyworth 6
Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric
Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the
Treatment of Schizophrenia 143 Gerard J. Marek, Bruce J. Kinon, David L.
McKinzie, Jeffrey M. Schkeryantz, and James A. Monn 7 AMPA Receptor
Positive Modulators 187 John A. Morrow, John K.F. Maclean, and Craig
Jamieson 8 Progress in the Exploration and Development of GlyT1 Inhibitors
for Schizophrenia 233 Jeffrey S. Albert and Michael W. Wood 9 Combined
Dopamine D2 and 5-Hydroxytryptamine (5-HT)1A Receptor Strategies for the
Treatment of Schizophrenia: A Pharmacological and Chemical Perspective 255
Andrew C. McCreary, Roelof W. Feenstra, and Caitlin A. Jones 10 5-HT2C and
5-HT6 Receptor Targeted Emerging Approaches in Schizophrenia 273 Sharon
Rosenzweig-Lipson, John Dunlop, Lee E. Schechter, Thomas A. Comery,
Jonathan Gross, and Karen L. Marquis 11 The Cholinergic Hypothesis: An
Introduction to the Hypothesis and a Short History 295 Joseph I. Friedman,
Isabella Kanellopoulou, and Vladan Novakovic 12 alpha7 Nicotinic
Acetylcholine Receptors in the Treatment of Schizophrenia 319 Mihály Hajós
and Bruce N. Rogers 13 Muscarinic Acetylcholine Receptors as Novel Targets
for the Development of Therapeutics for Schizophrenia 355 Christian C.
Felder, David L. McKinzie, Richard C. Thompson, and Bin Liu 14 Will
Modulation of Neuropeptide Receptors Produce the Next Generation of
Antipsychotic Drugs? A Focus on the Neurokinin and Neurotensin Systems 381
Lee A. Dawson, Paul W. Smith, and Jeannette M. Watson 15 GABA and
Schizophrenia 425 John H. Kehne and George D. Maynard Index 469